• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

A novel approach for cervical cancer using exosome

Research Project

Project/Area Number 16K11164
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Obstetrics and gynecology
Research InstitutionOsaka Medical College

Principal Investigator

Hayashi Masami  大阪医科大学, 医学部, 准教授 (00551748)

Co-Investigator(Kenkyū-buntansha) 大道 正英  大阪医科大学, 医学部, 教授 (10283764)
田中 良道  大阪医科大学, 医学部, 講師 (10625502)
田辺 晃子  大阪医科大学, 医学部, 非常勤講師 (70454543)
佐々木 浩  大阪医科大学, 医学部, 講師 (80432491)
寺井 義人  大阪医科大学, 医学部, 非常勤講師 (90278531)
藤原 聡枝  大阪医科大学, 医学部, 講師 (90707960)
Project Period (FY) 2016-04-01 – 2019-03-31
Project Status Completed (Fiscal Year 2018)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
KeywordsmiRNA / exosome / 子宮頚癌 / マイクロRNA / エクソソーム / 癌
Outline of Final Research Achievements

Cervical cancer (CC) is the fourth most common cancer in women with approximately 570000 new cases annually worldwide. Over the years, screening and early effective treatment has reduced the incidence and mortality of CC. However, the prognosis of advanced cervical cancer remains poor. Exosomes are isolated from many types of cells and contain many compounds such as proteins, lipids and nucleic acids including miRNA. In the current study, we extracted miR-22-highly contained exosomes and treated CC cells to investigate the effect of radiation therapy. Treatment of miR-22-highly contained exosomes into CC cells suppressed the expression of c-myc binding protein (MYCBP) and one of the c-myc target genes human telomerase reverse transcription (hTERT). Furthermore, administration of miR-22-containing exosomes showed increased radiation sensitivity in clonogenic assay. These results indicated that exosomal miR-22 can be a novel therapeutic tool for CC.

Academic Significance and Societal Importance of the Research Achievements

siRNA、miRNA等の核酸薬剤は、遺伝子治療において注目されているが、細胞への導入の際に、無毒化したウイルスベクターやリポフェクタミン等の導入剤が用いられることより、ウイルスベクターの生体内への安全性や、核酸薬剤が細胞内に導入される前に生体内で分解される可能性等の課題が残る。本研究では、生体内で分泌・運搬されるエクソソームをDDSに用いるため、毒性が低くかつ免疫原性のない治療になりうると考えられる。さらに、従来の薬剤と作用点が異なるため、従来の抗腫瘍薬との併用・相乗効果も期待でき、既存の治療に難治性を示す進行子宮頸癌への新たな治療戦略として大きなアドバンテージが期待される。

Report

(4 results)
  • 2018 Annual Research Report   Final Research Report ( PDF )
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (1 results)

All 2017

All Presentation (1 results)

  • [Presentation] MicroRNA-22を介した子宮頸癌の分子標的治療への応用2017

    • Author(s)
      中村真由美、林正美、橋田宗祐、丸岡寛、小西博巳、前田和也、田中良道、佐々木浩、寺井義人、大道正英
    • Organizer
      日本産婦人科学会学術講演会
    • Related Report
      2017 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi